Latest News for: scopus

Edit

Additional Proxy Soliciting Materials (Form DEFA14A) (Scopus Biopharma Inc)

Public Technologies 27 Oct 2021
SCOPUS BIOPHARMA INC ... SCOPUS BIOPHARMA INC ... The supplemental disclosures set forth below should be read in conjunction with the Definitive Proxy Statement, which should be read in its entirety, along with periodic reports and other information Scopus files with the Securities and Exchange Commission ... Scopus Biopharma Inc.
Edit

Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders (Scopus Biopharma Inc)

Public Technologies 11 Oct 2021
Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders. New York, New York, October 8, 2021 - Scopus BioPharma Inc.(Nasdaq ... Laster's pending claims against Scopus in the Delaware Court of Chancery ... About Scopus BioPharma ... Receive updates by following Scopus BioPharma on Twitter here ... scopus@reevemark.com ... Scopus Biopharma Inc.
Edit

Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders

Nasdaq Globe Newswire 08 Oct 2021
08, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc ... and Court Order approved by the Delaware Court of Chancery between Scopus and Morris C ... Laster’s pending claims against Scopus in the Delaware Court of Chancery.
Edit

Scopus BioPharma to Present at the LD Micro Main Event

Nasdaq Globe Newswire 05 Oct 2021
Scopus to present on the recent launch of Duet Therapeutics,�its wholly-owned subsidiary focused on immuno-oncology ... .
Edit

Scopus BioPharma to Present at the LD Micro Main Event (Scopus Biopharma Inc)

Public Technologies 05 Oct 2021
Scopus BioPharma to Present at the LD Micro Main Event. Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology ... New York, New York, October 5, 2021 - Scopus BioPharma Inc.(Nasdaq ... Duet Therapeutics integrates the immunotherapy assets of Scopus and Olimmune, creating the Duet Platform.
Edit

Scopus BioPharma to Present at MicroCap Rodeo’s Fall Harvest Best Ideas Conference

Nasdaq Globe Newswire 01 Oct 2021
Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology ... .
Edit

Scopus BioPharma Retaining Counsel to Investigate Unusual Market Activity

Nasdaq Globe Newswire 01 Oct 2021
NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq. “SCPS”), a clinical-stage biopharmaceutical company, announced today that it is retaining Boies Schiller Flexner LLP to conduct a market manipulation investigation ... .
Edit

Scopus BioPharma to Present at MicroCap Rodeo’s Fall Harvest Best Ideas Conference (Scopus Biopharma Inc)

Public Technologies 01 Oct 2021
Scopus BioPharma to Present at MicroCap Rodeo's Fall Harvest Best Ideas Conference. Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology ... New York, New York, October 1, 2021 - Scopus BioPharma Inc.(Nasdaq ... Olimmune was acquired by Scopus in June 2021 ... About Scopus BioPharma.
Edit

INDEMNIFICATION AGREEMENT (Form 8-K) (Scopus Biopharma Inc)

Public Technologies 30 Sep 2021
... company ("HCFP"), Scopus BioPharma Inc., a Delaware corporation (the "Company"), and HCFP's principals, Ira Greenspan, Joshua Lamstein, and Robert Gibson (together, the "Principals") ... Scopus BioPharma Inc ... Scopus BioPharma Inc ... Scopus Biopharma Inc.
Edit

Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Release of Preclinical Data Being Presented at ...

Nasdaq Globe Newswire 29 Sep 2021
Data from two different studies benchmark Duet’s proprietary bifunctional oligonucleotides against immune checkpoint inhibitors (“Checkpoint Inhibitors”) in lymphoma and prostate tumor models in mice ... .
Edit

Scopus BioPharma’s Subsidiary — Duet Therapeutics — Announces Release of Preclinical Data Being Presented at 17th Annual Meeting of the Oligonucleotide Therapeutics Society (Scopus Biopharma Inc)

Public Technologies 29 Sep 2021
Scopus BioPharma's Subsidiary - Duet Therapeutics - Announces Release of Preclinical Data Being Presented at 17th Annual Meeting of the Oligonucleotide Therapeutics Society ... New York, New York, September 29, 2021 - Scopus BioPharma Inc.(Nasdaq ... Duet Therapeutics is a wholly-owned subsidiary of Scopus ... Olimmune was acquired by Scopus in June 2021.
Edit

Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Release of Preclinical Data ...

Kentucky New Era 29 Sep 2021
29, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc ... Alan Horsager, Ph.D., President and Chief Executive Officer of Duet Therapeutics and President — Immuno-Oncology of Scopus, is presenting data in talks entitled. ... Duet Therapeutics is a wholly-owned subsidiary of Scopus ... Olimmune was acquired by Scopus in June 2021 ... About Scopus BioPharma.
Edit

Scopus BioPharma to Adjourn 2021 Annual Meeting of Stockholders

Nasdaq Globe Newswire 28 Sep 2021
NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq ... Laster, M.D. in connection with pending claims brought by Dr ... The company and Dr ... .
×